Vitamin D3, MS and the Coimbra Protocol
The founders and backers of D-light-full have personal experience of autoimmune diseases, either as patients themselves or as relatives of sufferers. They see orthomolecular treatment with ultra-high-dose vitamin D3 in accordance with the Coimbra Protocol as an effective option for a better quality of life.
Vitamin D3 study at Charité in Berlin
D-light-full is supporting Germany’s first large-scale observational study on the effect of high-dose vitamin D3 treatment for multiple sclerosis (MS) in accordance with the Coimbra Protocol at the Charité university hospital in Berlin. In March 2021, the NeuroCure Research Center at Charité in Berlin started the first large-scale clinical study to observe the effect of high-dose vitamin D3 therapy in accordance with the Coimbra Protocol. Over a three-year period, 100 patients with relapsing-remitting multiple sclerosis will be treated by a certified protocol doctor for the Coimbra Protocol and have regular medical examinations at Charité as part of an observational study. The study was set up at the instigation of Coimbraprotokoll gUGmbH, a charitable organisation financed by the Falk-Stiftung für Gesundheit und Bildung in Nuremberg. In cooperation with D-light-full, Coimbraprotokoll gUGmbH is giving all study participants a D-light-full voucher worth €200 each year. This is designed to ensure that all participants use a high-quality vitamin D preparation in a guaranteed dose form and with a high level of bioavailability. The vouchers are managed by Coimbraprotokoll gUGmbH and can be obtained from them on presentation of proof of participation in the study. The vouchers can be used in the D-light-full online shop. More details about the study can be found on the Coimbraprotokoll gUGmbH website: https://coimbraprotokoll.de/projekte/
We will be happy to answer them. Simply send us a brief email: email@example.com